Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Feb 16, 2017	Evoke Pharma Announces Pricing of Public Offering of Common Stock SOLANA BEACH, Calif., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that it has priced an underwritten public offering of 2,413,793 shares of its common stock at a price to	View HTML Evoke Pharma Announces Pricing of Public Offering of Common Stock 15.2 KB
Toggle Summary Feb 15, 2017	Evoke Pharma Announces Proposed Public Offering of Common Stock SOLANA BEACH, Calif., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it intends to offer and sell shares of its common stock in a "firm commitment" underwritten	View HTML Evoke Pharma Announces Proposed Public Offering of Common Stock 15.4 KB
Toggle Summary Feb 15, 2017	FDA Exempts Evoke from Requirement for Human Factor Validation Study Company reaffirms NDA submission by year end 2017	View HTML FDA Exempts Evoke from Requirement for Human Factor Validation Study 194 KB
Toggle Summary Jan 09, 2017	Evoke Pharma to Attend 2017 JPMorgan Healthcare Conference SOLANA BEACH, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer, and its Chief Business Officer, Matt	View HTML Evoke Pharma to Attend 2017 JPMorgan Healthcare Conference 14.7 KB
Toggle Summary Jan 04, 2017	Evoke Provides Additional Data Demonstrating Statistically Significant Benefit for Gimoti in Moderate to Severe Patients in Phase 3 Diabetic Gastroparesis Trial Nausea and abdominal pain symptoms significantly reduced in patients with higher symptom severity	View HTML Evoke Provides Additional Data Demonstrating Statistically Significant Benefit for Gimoti in Moderate to Severe Patients in Phase 3 Diabetic Gastroparesis Trial 25.5 KB
Toggle Summary Dec 15, 2016	Evoke Receives Positive NDA Submission Guidance from US FDA for Gimoti Healthy volunteer bridging study to oral metoclopramide to be completed and submitted in NDA with existing safety and efficacy data	View HTML Evoke Receives Positive NDA Submission Guidance from US FDA for Gimoti 16.2 KB
Toggle Summary Nov 09, 2016	Evoke Pharma Reports Third Quarter 2016 Results SOLANA BEACH, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2016.	View HTML Evoke Pharma Reports Third Quarter 2016 Results 27.6 KB
Toggle Summary Nov 01, 2016	Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2016 Financial Results SOLANA BEACH, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the third quarter 2016 on Wednesday, November 9, 2016,	View HTML Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2016 Financial Results 12 KB
Toggle Summary Sep 07, 2016	Evoke Pharma Announces Positive Non-Clinical Pre-NDA Meeting with FDA for Gimoti SOLANA BEACH, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) (the "Company"), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, today announced that it has completed a pre‑New Drug Application (NDA) meeting with the U.S.	View HTML Evoke Pharma Announces Positive Non-Clinical Pre-NDA Meeting with FDA for Gimoti 17.1 KB
Toggle Summary Sep 06, 2016	Evoke Pharma to Present at Rodman & Renshaw 18th Annual Global Investment Conference SOLANA BEACH, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer, R.Ph., President and CEO will be presenting at the Rodman & Renshaw 18 th Annual	View HTML Evoke Pharma to Present at Rodman & Renshaw 18th Annual Global Investment Conference 12.3 KB